All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Extended-release intramuscular aripiprazole for maintenance pharmacotherapy in schizophrenia and related disorders

Author(s): Leon Tourian,Howard C Margolese

Aripiprazole is a third-generation antipsychotic. It is prepared in many different formulations including oral, intravenous and intramuscular. The intramuscular option is currently available in fast-acting form while the long-acting (extended-release, depot) formulation was just approved by the US FDA. The purpose of this article is to review the current literature regarding the long-acting formulation of aripiprazole. Medical literature published in English on ‘aripiprazole’ or ‘Abilify®’ (Otsuka America Pharmaceutical Inc., MD, USA) was found using Pubmed, Medline and EMBASE. Publications containing the words ‘depot’, ‘long-acting’ or ‘intramuscular’ in their title or abstract were utilized. In total, two publications were reviewed for the purposes of this article. There is a scarcity of publications on the effectiveness of long-acting aripiprazole in the treatment of schizophrenia and schizoaffective disorder. However, the available literature suggests that aripiprazole depot is a well tolerated, maintenance treatment option for schizophrenia.


Share this       
izmir escort bayan izmir rus escort bursa escort bayan rus escort izmir escort porno indir porno izle mobil porno eskişehir escort burdur escort bartın escort havalandırma türk takipçi satın al izmir escort bursa escort türk porno escort bayan

paper io